Clinical Trials

Have you been diagnosed with peripartum cardiomyopathy and are within 5 months of your due date? This study is evaluating the effectiveness of a medicine called bromocriptine to treat peripartum cardiomyopathy, or weakness of the heart muscle that occurs during or shortly after pregnancy. To participate in this study, you must be at least 18 years old, diagnosed with peripartum cardiomyopathy, and within 5 months of your delivery date. This study takes place in Pittsburgh, Pennsylvania.

Are you an adult with a history of heart failure, or do you just want to help people who do? This study is recruiting people with heart failure and people with normal heart function to explore the role of the gut microbiome in heart and blood vessel function. Participants in this study must be at least 18 years old and willing to provide blood and stool samples. This study takes place in Gainesville, Florida.

Do you have heart failure with preserved ejection fraction (HFPEF)? This study is testing the efficacy of a diuretic medicine called spironolactone that stops your body from absorbing too much salt and keeps your potassium levels from dropping too low. Participants of this study must be between 50 and 99 years old and already taking diuretic medicine. This study takes place in multiple locations across the United States and Sweden.

Are you the parent or caregiver of a 12- to 15-year-old child with asthma who uses an inhaled corticosteroid to treat symptoms? This study is testing whether a mobile health tool, called AIM2ACT, can help adolescents and their caregivers manage symptoms of asthma. To participate in this study, you must be between 18 and 70 years old. This study takes place in Gainesville, Florida.

Do you or your child have severe asthma that is not easily controlled by inhaled corticosteroids? This study evaluates the use of five different asthma medicines to treat adults and adolescents with severe asthma. To participate in this study, you or your child must be 12 years old or older. This study takes place in multiple locations across the United States.

Do you have a child with Down syndrome and obstructive sleep apnea who is treated with positive airway pressure (PAP)? This study is testing a new intervention that was informed by the families to help children with Down syndrome and obstructive sleep apnea stick to their PAP treatment. The study will test the effectiveness of a new treatment plan that involves regular telephone and in-person check-ins with a PAP specialist. This study is for 6 -18 year old and is located in Cincinnati, Ohio; and Philadelphia, Pennsylvania.

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.

The study is to investigate that the worsening orthostatic tachycardia and symptoms after glucose ingestion in POTS patients are due to a greater increase in splanchnic venous capacitance and excessive blood pooling during an orthostatic challenge.

Do you have a family history of high cholesterol? Researchers are studying whether a particular medication can lower cholesterol in people with a family history of high cholesterol. You may be able to participate if you are 18 to 69 years old, have not had a heart attack or stroke recently, and do not have uncontrolled high blood pressure. This study will take place in Nashville, Tennessee.

The Investigators propose a randomized trial of smart texts versus usual care for 6 months. The Investigators will randomize 100 PAH patients to the mHealth intervention or usual care. The Investigators will test the effect of a text-based mHealth intervention on HRQOL in PAH using the PAH-specific emPHasis-10 questionnaire. The Investigators will also test the effect of an mHealth intervention on exercise capacity, measured by a supervised home-based 6MWD test. Finally, the Investigators will examine the effect of the intervention on time to clinical worsening (composite of PAH therapy escalation, PAH hospitalization, and death) one year after randomization.